2. Academic Validation
  3. A Comparative Assessment Study of Known Small-molecule GPVI Modulators

A Comparative Assessment Study of Known Small-molecule GPVI Modulators

  • ACS Med Chem Lett. 2022 Jan 20;13(2):171-181. doi: 10.1021/acsmedchemlett.1c00414.
Holly Foster 1 2,  Clare Wilson 2,  Julia S Gauer 2,  Rui-Gang Xu 2,  Mark J Howard 1,  Iain W Manfield 3,  Robert Ariëns 2,  Khalid Naseem 2,  Lewis R Vidler 4,  Helen Philippou 2,  Richard Foster 1 2
Affiliations

Affiliations

  • 1 School of Chemistry, University of Leeds, Leeds LS2 9JT, U.K.
  • 2 Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds LS2 9JT, U.K.
  • 3 Faculty of Biological Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, U.K.
  • 4 UCB, Slough, SL1 3WE, U.K.
PMID: 35178172 DOI: 10.1021/acsmedchemlett.1c00414
Abstract

The GPVI platelet receptor was recently validated as a safe antiplatelet target for the treatment of thrombosis using several peptidic modulators. In contrast, few weakly potent small-molecule GPVI antagonists have been reported. Those that have been published often lack evidence for target engagement, and their biological efficacy cannot be compared because of the natural donor variability associated with the assays implemented. Herein, we present the first side-by-side assessment of the reported GPVI small-molecule modulators. We have characterized their functional activities on platelet activation and aggregation using flow cytometry as well as light transmission and electrical impedance aggregometry. We also utilized microscale thermophoresis (MST) and saturation transfer difference (STD) NMR to validate GPVI binding and have used this along with molecular modeling to suggest potential binding interactions. We conclude that of the compounds examined, losartan and compound 5 are currently the most viable GPVI modulators.

Figures
Products